Kratom, Lead, and the Pregnancy Risk No One Is Owning
New evidence pack: Commercial kratom products contain measurable lead (0.6–1.0+ µg/g). Neonatal case reports confirm that pregnant women are using kratom daily — meaning the same fetuses are exposed to repeated lead ingestion during organ development, on top of neonatal withdrawal risks.
Lead found in Golden Monk White Powder (per COA). At 5 g/day → ~5 µg lead daily.
Lead in Golden Monk Red Powder. Multiple batches, multiple measurable findings.
Neonatal abstinence syndrome cases prove prenatal kratom use → those infants also ingested lead daily in utero.
Key evidence from the full report:
- Lead crosses the placenta and is linked to spontaneous abortion, low birth weight, and neurodevelopmental harm.
- Published neonatal case reports (included below) document kratom withdrawal & NICU stays — direct proof of pregnancy use.
- With lead contamination confirmed by independent lab analysis, every daily kratom dose during pregnancy delivers an avoidable toxic heavy metal.
Another Kratom NDI Fails — The Evidence Does Not Carry the Argument
TNT Manufacturing (d/b/a MitWellness) submitted a 75% mitragynine extract as a New Dietary Ingredient. FDA found identity, safety, and manufacturing gaps. The conclusion: introduction into interstate commerce is prohibited under federal law.
— FDA letter to Todd Underwood / TNT Manufacturing (NDIfail2.pdf)
Inside the Kratom Advocacy Machine: One Click, Identical Letters
The Global Kratom Coalition’s “Advocacy Buddy” generates complete, persuasive letters from minimal input — including the placeholder “Xx”. The tool standardizes language, assigns identity labels, and delivers identical messages to legislators, creating the illusion of grassroots testimony.
Kratom Shots, Alcohol Content, and Kansas Lab Testing
Independent laboratory testing of popular kratom shot products revealed undeclared alcohol content, significant label inaccuracies, and marketing that obscures actual ingredients. The findings raise questions about product safety, consumer deception, and the gap between KCPA labeling requirements and real-world compliance.
Absolute Shock to Nobody: Kratom Consumer Protection Acts Failed
A national analysis in Addiction of 8,919 kratom poison center exposures found that Kratom Consumer Protection Acts (KCPAs) performed statistically no better than having no meaningful regulation. KCPA states showed no significant differences in exposure rates, severe outcomes, hospitalizations, or healthcare utilization compared to unrestricted states.
The study’s conclusion: “No statistically significant differences were identified between other regulatory categories.” That means KCPA states look just like unrestricted states — the “consumer protection” promise is regulatory theater.
FDA and Kratom — Official Agency Statement
U.S. Food & Drug Administration public health summary on kratom
FDA NDI Review & Denial — Dried Kratom Leaf
Johnson Foods, LLC (2023)
Kratom Vendor Terms of Service Admit Opioid-Like Risks
Vendor Policy Disclosure Analysis
Kratom: Consolidated Briefing for Lawmakers
This page provides a centralized, source-based briefing on kratom for legislators, regulators, and policy staff. It consolidates MAHA’s surveillance data, scientific literature, regulatory analysis, and legislative case studies into a single reference point.
I. Surveillance & Harm Data
FDA Adverse Event Reporting
Poison Control & Mortality Data
Medical Examiner Data
II. Core Alkaloid & Scientific Information
III. Current Regulatory Claims & Industry Submissions
FDA Human Kratom Study: Why the Results Strengthen the Case for Schedule I
MAHA analysis of the Phase I human dose study showing opioid-like effects, statistically significant drug liking, and measurable exposure to 7‑hydroxymitragynine.
Pinney Associates “Eight-Factor Analysis”
Review of the industry-funded report submitted to regulators, highlighting buried admissions about metabolism and opioid potency.
Michigan HB 4969: What Lawmakers Were Told
Structured review of testimony regarding FDA posture, natural leaf claims, and 7‑hydroxymitragynine distinctions.
How Kansas Was Misled to Pass the KCPA
Analysis of exhibits submitted to lawmakers and what the underlying science actually demonstrates.
2004 Opioid Testimony & Today’s Kratom Debate
Compares early opioid-era risk framing with arguments currently raised in kratom policy discussions.
IV. State Regulatory Outcomes & Enforcement Gaps
- California: Treating Kratom as an Unapproved Drug
- What Congress Wasn’t Told
- FD&C Act Violations Explained
- New York Statutory Contradiction
- Florida SB 994 Enforcement Issues
- Wyoming Kratom Bill: A Fig Leaf, Not Public Health
V. Scheduling, Registries & Structural Analysis
- Ohio Board of Pharmacy – 8-Factor Analysis
- Extraction & Scheduling Rationale
- KCPA Structural Limitations & Public-Health Risk
- Nebraska Kratom Registry Review
- FDA NDI Loophole & Enforcement Discretion
- Limitations of the Huestis Human Dose Study
VI. Intended Use
This briefing is intended to support legislative research, regulatory review, enforcement hearings, and policy analysis. All materials are provided as primary sources or direct analyses without editorial framing.
Mothers Against Herbal Abuse (MAHA)
https://www.mothersagainstherbalabuse.org
Contact: policy@mothersagainstherbalabuse.org